Is Mounjaro Safe During Pregnancy? The Honest Answer

Step 1: Understand why this medicine is not used in pregnancy

Tirzepatide belongs to a class of medicines that activate gut-hormone receptors involved in appetite regulation and blood-sugar control. During the clinical trial programme that led to Mounjaro's UK licence, pregnant women were not enrolled, so there is simply no human evidence on which to base a safety reassurance. That absence of data is itself the reason for caution, not an oversight.

Animal studies, however, did raise concerns. In reproductive toxicology studies carried out during the drug's development, tirzepatide was associated with reduced foetal growth and other developmental findings at doses relevant to human exposure. These findings were sufficient for the licence to carry a clear contraindication for pregnancy. The NHS patient information for tirzepatide states directly that Mounjaro must not be used if you are pregnant or planning to become pregnant.

The picture is the same for breastfeeding. It is not known whether tirzepatide passes into breast milk. Because the risk to a nursing infant cannot be ruled out, the medicine should not be used while breastfeeding. If you want a fuller overview of Mounjaro side effects as they relate to pregnancy, our clinical team has covered this in detail. This is not a speculative precaution, it reflects a genuine absence of safety data in this population.

Step 2: Contraception and the four-week rule while on treatment

For women who are not pregnant but are using Mounjaro for weight management, contraception planning is an active part of treatment. The MHRA and NHS England both advise using effective contraception throughout the course of tirzepatide treatment and during the wash-out period before trying to conceive.

There is a specific interaction to know about if you take the oral contraceptive pill. Tirzepatide slows gastric emptying, which can reduce how much of an oral medicine is absorbed. NHS guidance (the NHS England weight-management injections page sets this out clearly) recommends adding a non-oral contraceptive method (such as condoms) for the first four weeks of Mounjaro treatment and for four weeks after each dose increase. This is a practical, temporary precaution, not a permanent change. Non-oral contraception (patches, implants, hormonal coils, condoms) is unaffected by this interaction.

If you are on the pill and starting Mounjaro through a service like a regulated clinical consultation, raise this with your prescriber at the outset so the right plan is in place from day one.

Step 3: What to do if you become pregnant while taking Mounjaro

Discovering a pregnancy during treatment feels alarming, that is completely understandable, and it does not mean harm has already occurred. What matters most is acting quickly and calmly.

Stop taking Mounjaro immediately. Then contact your GP or midwife the same day. They can advise on monitoring, refer you to an obstetric team if needed, and ensure any implications for your wider health (including blood-sugar management if tirzepatide was also being used for type 2 diabetes) are addressed. Do not try to complete a current pen or manage the transition yourself. You can also read more about the specific pregnancy risk considerations for Mounjaro covered by our clinical team.

Reporting suspected side effects during pregnancy, including any pregnancy outcome following medicine exposure, can be done via the MHRA Yellow Card scheme. This kind of reporting actively contributes to the evidence base for future guidance, it is genuinely useful, not just bureaucratic.

Step 4: Planning for treatment after pregnancy or breastfeeding

Mounjaro is not permanently off the table. Once a pregnancy has ended and breastfeeding has concluded, weight management treatment can be reconsidered with a prescriber who has the full clinical picture. Many patients ask whether tirzepatide is safe during pregnancy before making decisions about timing, and our clinical team has addressed that question directly. There is no evidence that previous tirzepatide use affects fertility or future pregnancies, though this should be discussed individually.

If you had been making good progress with weight management before a planned pregnancy, the pause in treatment is exactly that, a pause. You can explore the broader weight-loss treatment options available and, when the time is right, have a fresh consultation with a clinician. Our prescribers review every case individually; there is no assumption that a returning patient picks up exactly where they left off. Read more about Mounjaro's side-effect profile generally, or about how tirzepatide works as a starting point for that future conversation. If you are still weighing up whether to restart after having a baby, our page on whether Mounjaro is safe for pregnant women explains the clinical reasoning behind current guidance.